BioCryst Pharmaceuticals Inc (BCRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 4:51 PM ET
BioCryst Pharmaceuticals Inc (BCRX) Statistics
BioCryst Pharmaceuticals (BCRX) has a market cap of $1.96B and an enterprise value of $2.26B. Its return on invested capital of 24937.07% compares with a 7.96% median across 10 similar companies. Its share count is up 21.63% from a year earlier.
Total Valuation
Enterprise value is 15.28% above the market cap, as debt exceeds cash.
| Market Cap | $1.96B |
|---|---|
| Enterprise Value | $2.26B |
| Latest price (Nov 17, 2026) | $7.50 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 2.0x.
| P/E Ratio | 4.4x |
|---|---|
| P/S Ratio | 2.0x |
| Forward P/S | 2.7x |
| P/FCF Ratio | 5.2x |
| P/OCF Ratio | 5.3x |
Enterprise Valuation
Counting debt and cash, the company is valued at 6.1x free cash flow.
| EV / Sales | 2.3x |
|---|---|
| EV / FCF | 6.1x |
Price Statistics
The stock is up 5.93% over 52 weeks and trades 7.98% below its 50-day average.
| Beta (1Y) | 0.66 |
|---|---|
| 52-Week Change | +5.93% |
| 1-Month Change | -7.06% |
| 3-Month Change | -25.52% |
| 6-Month Change | -14.48% |
| 5-Year Change | -43.27% |
| 10-Year Change | +109.14% |
| Total Return (1Y) | +5.93% |
| Total Return (3Y CAGR) | +11.92% |
| Total Return (5Y CAGR) | -8.59% |
| Return vs SPY (1Y) | -4.42% |
| Max Drawdown (1Y) | -32.94% |
| Max Drawdown (3Y) | -46.01% |
| Sharpe Ratio (1Y) | 0.15 |
| Correlation with SPY (1Y) | 0.19 |
| 50-Day Average | $8.15 |
| 200-Day Average | $8.81 |
| 52-Week Range | $6.23 to $11.22 |
| RSI (14 Days) | 39.4 |
| Average Volume (20 Days) | 5.26M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.71x current liabilities.
| Current Ratio | 2.71x |
|---|---|
| Quick Ratio | 2.64x |
| Debt / FCF | 1.08x |
| Interest Coverage | 3.67x |
Returns and Efficiency
Return on invested capital is 24937.07% over the last 12 months.
| Return on Assets (ROA) | -60.85% |
|---|---|
| Return on Invested Capital (ROIC) | 24937.07% |
| Return on Capital Employed (ROCE) | -72.68% |
| ROA (5Y Average) | -17.37% |
| Asset Turnover | 1.85x |
| Inventory Turnover | 2.05x |
| Receivables Turnover | 8.27x |
| Cash Conversion Cycle | -12 days |
Scores
BCRX has an Altman Z-Score of -3.13, in the distress zone below 1.81, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -3.13 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $961.51M over the last 12 months is up 60.30% from the 12 months before.
| Revenue | $961.51M |
|---|---|
| Revenue Growth (YoY) | +60.30% |
| Gross Profit | $941.20M |
| Operating Income | -$289.42M |
| Pretax Income | -$354.73M |
| Net Income | -$359.66M |
| EBITDA | -$287.57M |
| EBIT | -$287.27M |
| Reported EPS (TTM) | $1.70 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
| Cash and Equivalents | $96.97M |
|---|---|
| Total Debt | $396.23M |
| Net Debt | $299.26M |
| Net Debt Per Share | $1.17 |
| Working Capital | $335.32M |
| Shareholder Equity | -$397.38M |
| Total Assets | $591.07M |
| Total Liabilities | $988.45M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.65M of capital spending, operating cash flow left $365.85M of free cash flow.
| Operating Cash Flow | $367.49M |
|---|---|
| Capital Expenditures | $1.65M |
| Free Cash Flow | $365.85M |
| FCF Per Share | $1.43 |
| Depreciation and Amortization | $5.22M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -30.10%, against a 5-year average of -32.15%.
| Gross Margin | 97.89% |
|---|---|
| Operating Margin | -30.10% |
| Pretax Margin | -36.89% |
| Net Margin | -37.41% |
| EBITDA Margin | -29.91% |
| EBIT Margin | -29.88% |
| FCF Margin | 38.05% |
| Gross Margin (5Y Average) | 97.36% |
| Operating Margin (5Y Average) | -32.15% |
| Net Margin (5Y Average) | -53.25% |
Growth
Revenue grew 47.82% a year over 3 years.
| Revenue Growth (3Y CAGR) | +47.82% |
|---|---|
| Revenue Growth (5Y CAGR) | +117.89% |
Dividends and Yields
BCRX does not pay a dividend. Its free cash flow yield is 19.08%.
| Earnings Yield | 22.73% |
|---|---|
| FCF Yield | 19.08% |
| Buyback Yield | -1.59% |
| Shareholder Yield | -1.59% |
Peer Position
Against 12 similar companies, BCRX has the 11th highest P/E and the 6th highest P/S.
P/E RatioPeer median 10.7x
P/S RatioPeer median 2.0x
ROICPeer median 7.96%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.45%
| P/E Ratio | 4.4x vs 10.7x median |
|---|---|
| P/S Ratio | 2.0x vs 2.0x median |
| ROIC | 24937.07% vs 7.96% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +60.30% vs +10.45% median |
Analyst Forecast
Consensus estimates put revenue growth at -8.27% and EPS growth at -19.52% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -8.27% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -19.52% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About BCRX
What is BCRX's market cap?
BioCryst Pharmaceuticals has a market cap of $1.96B. Its enterprise value, which adds debt and subtracts cash, is $2.26B.
What is BCRX's P/E ratio?
BioCryst Pharmaceuticals has a trailing P/E ratio of 4.4x.
How many shares of BCRX are outstanding?
BioCryst Pharmaceuticals has 255.63M shares outstanding. The count is up 21.63% from a year earlier.
Does BCRX pay a dividend?
No. BioCryst Pharmaceuticals does not pay a dividend.
How much debt does BCRX have?
BioCryst Pharmaceuticals has $396.23M of total debt and $96.97M of cash and equivalents, a net debt position of $299.26M.
BCRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts